Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Damoctocog · 1 trial · 1 indication
Area under the concentration time profile curve.
| Arm | Type | Description |
|---|---|---|
| BAY94-9027 and Elocta | EXPERIMENTAL | Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment |
| Elocta and BAY94-9027 | EXPERIMENTAL | Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment |
| Name | Type | Description |
|---|---|---|
| Damoctocog (Jivi, BAY94-9027) | DRUG | 60 international units (IU)/kg, given as a 10 minute injection, 1 dose |
| Elocta | DRUG | 60 IU/kg, given as a 10 minute injection, 1 dose |
Inclusion Criteria: * Males, age 18 to 65 years. * Subjects with Severe Hemophilia A with a documented plasma FVIII level of \< 1% * ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records Exclusion Criteria: * Evidence of current or past inhibitor antibody: * History of any...
Damoctocog is an investigational small molecule being developed for the treatment of Hemophilia A. It is currently in Phase 1 clinical development. The drug is being studied in a clinical trial that has been completed, which enrolled 18 male participants aged 18 years and older in Bulgaria.
Damoctocog is being developed by Bayer AG, a pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The drug is currently in Phase 1 clinical development for the treatment of Hemophilia A.
Damoctocog is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial for Damoctocog has been completed, with a total enrollment of 18 participants.
Damoctocog has one completed clinical trial registered under NCT03364998, titled 'BAY94-9027 PK Study Comparing to Another Long Acting Product'. This Phase 1 study enrolled 18 male participants with Hemophilia A in Bulgaria. The trial was controlled and randomized, but not double-blinded.
Yes, Damoctocog is also known as BAY94-9027. The clinical trial NCT03364998, which studied Damoctocog, is titled 'BAY94-9027 PK Study Comparing to Another Long Acting Product'. This trial was a Phase 1 study in Hemophilia A.